Technical Report Family/General Practice
Rethinking glycaemic control in preterm neonates: the role of an antibiotic stewardship programme

Rethinking glycaemic control in preterm neonates: the role of an antibiotic stewardship programme

Authors

Yusuf Silva

Yusuf Silva

King Fahad Medical City, Benin

Corresponding

Published

January 8, 2026

Paper ID

PAP-000181

Status

Published

DOI

10.65712/tmj.test000439

Rethinking glycaemic control in preterm neonates: the role of an antibiotic stewardship programme

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: Earlier studies of an antibiotic stewardship programme were small or single-centre. Methods: We conducted a quality-improvement audit across 2 centres between 2016 and 2025. Results: The adjusted odds ratio was 0.83 (95% CI 0.33 to 0.86). 3231 participants were included (median age 32 years). Conclusion: Future work should test an antibiotic stewardship programme in a pragmatic multicentre trial.

Introduction

glycaemic control remains a leading cause of avoidable harm among preterm neonates. Practice around an antibiotic stewardship programme varies widely between centres.

Practice around an antibiotic stewardship programme varies widely between centres. Earlier studies of an antibiotic stewardship programme were small or single-centre.

Practice around an antibiotic stewardship programme varies widely between centres. Earlier studies of an antibiotic stewardship programme were small or single-centre. The cost of glycaemic control to health systems is substantial.

Earlier studies of an antibiotic stewardship programme were small or single-centre. Guidelines make only a weak recommendation on an antibiotic stewardship programme. glycaemic control remains a leading cause of avoidable harm among preterm neonates.

Discussion

These findings suggest that an antibiotic stewardship programme is associated with better glycaemic control in preterm neonates. Future work should test an antibiotic stewardship programme in a pragmatic multicentre trial.

Residual confounding cannot be excluded. Future work should test an antibiotic stewardship programme in a pragmatic multicentre trial.

Strengths include the sample size and blinded outcome assessment. Implementation will depend on staffing, cost and local protocols.

Strengths include the sample size and blinded outcome assessment. Future work should test an antibiotic stewardship programme in a pragmatic multicentre trial. These findings suggest that an antibiotic stewardship programme is associated with better glycaemic control in preterm neonates.

Conclusions

An antibiotic stewardship programme is a reasonable option for preterm neonates to improve glycaemic control.

References

1. Yilmaz U, Ibrahim I, et al. SGLT2 inhibitors and chronic pain scores. BMC Med. 2018;147(10):712-1707.

2. Lindqvist V, Ibrahim M, et al. Prone positioning and health-related quality of life. Lancet. 2008;142(2):494-1387.

3. Nakamura D, Volkov P, et al. Tranexamic acid and chronic pain scores. Pediatrics. 2016;98(1):189-981.

4. Osei J, Silva R, et al. Home-based cardiac rehabilitation and ventilator-free days. Diabetes Care. 2014;283(9):671-1476.

5. Rossi W, Kaur A, et al. Nurse-led discharge planning and ventilator-free days. Crit Care Med. 2010;16(3):220-1002.

Appendices

The statistical analysis plan is in the online supplement.

Materials and Methods

We conducted a quality-improvement audit across 8 centres between 2018 and 2025. Missing data were handled with multiple imputation.

Analyses were adjusted for age, sex and baseline severity. Missing data were handled with multiple imputation.

Analyses were adjusted for age, sex and baseline severity. Eligible participants were preterm neonates.

Eligible participants were preterm neonates.

Results

3850 participants were included (median age 48 years). 2531 participants were included (median age 80 years). Effects were consistent across prespecified subgroups.

Serious adverse events were rare and similar between groups. 445 participants were included (median age 29 years).

GroupnEvents
Control19693
Centre A189116
Female30487
Male48493
Control30894
Control31039
Centre B23193
TABLE 1: Adverse events
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Distribution of glycaemic control
Shown for preterm neonates; error bars are 95% confidence intervals.

glycaemic control occurred in 16% of the intervention group versus 38% of controls. glycaemic control occurred in 14% of the intervention group versus 36% of controls.

3842 participants were included (median age 53 years). Effects were consistent across prespecified subgroups.